Regeneron Q1 revenue rises 19% to $3.6 billion; GAAP EPS falls 7% to $6.75
Regeneron reported first quarter 2026 revenues of $3.6 billion, up 19% from a year earlier, and non-GAAP earnings per share of $9.47, up 15%. GAAP net income fell 10% to $727 million, and GAAP EPS fell 7% to $6.75, which the company said includes a $0.82 negative impact from acquired in-process R&D; the company also cut its full-year 2026 GAAP gross margin guidance and authorized a new $3.0 billion share repurchase program.
Key points
- Total revenues were $3,605 million, up 19% from $3,029 million in Q1 2025.
- GAAP net income was $727 million, down 10%, and GAAP EPS was $6.75, down 7%; non-GAAP EPS was $9.47, up 15%.
- Full-year 2026 GAAP gross margin on net product sales guidance was lowered to 77%–78% from 79%–80%; other guidance was unchanged or raised.
- The board authorized a new $3.0 billion share repurchase program in April 2026, and a $0.94 per share dividend was declared.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.